Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 31, 2006. The report serves as a notification of transactions involving a Director, specifically Dr. J-P Garnier, regarding changes in his interest in the company's American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes
The material change reported is the exercise of share options and subsequent sale of ADSs by Dr. J-P Garnier:
- Option Exercise: On October 30, 2006, Dr. Garnier exercised options over 68,411 ADSs granted in 1996 at a price of $28.159 per ADS.
- Share Sale: On the same date, 45,500 ADSs were sold at an average price of $53.12.
- Resulting Holding: Following the transaction, Dr. Garnier's total shareholding stands at 529,769.32 ADSs, including 217,892 ADSs earned but deferred.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. The transaction is noted to be in accordance with Disclosure Rule 3.1.4R(1)(b). The filing notes that Dr. Garnier's holding is equivalent to more than 16 times his annual basic salary based on the option exercise price.
Key Facts for Investor Verification
- Verify the total number of ADSs held by Dr. J-P Garnier (529,769.32) and the portion deferred (217,892).
- Confirm the exercise price ($28.159) and sale price ($53.12) for the October 30, 2006 transactions.
- Note that the options exercised were granted in 1996 under the SmithKline Beecham Employee Share Option Plan 1991 and were set to lapse on November 20, 2006.